MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Protagonist Therapeutics Inc

Cerrado

SectorSanidad

64.91 1.34

Resumen

Variación precio

24h

Actual

Mínimo

63.71

Máximo

65.05

Métricas clave

By Trading Economics

Ingresos

-23M

-35M

Ventas

-23M

5.5M

P/B

Media del Sector

93.057

35.739

Margen de beneficios

-626.956

Empleados

130

EBITDA

-23M

-42M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+13.67% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

858M

4.2B

Apertura anterior

63.57

Cierre anterior

64.91

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Protagonist Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 mar 2025, 13:59 UTC

Principales Movimientos del Mercado

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Comparación entre iguales

Cambio de precio

Protagonist Therapeutics Inc previsión

Precio Objetivo

By TipRanks

13.67% repunte

Estimación a 12 Meses

Media 72.75 USD  13.67%

Máximo 82 USD

Mínimo 65 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Protagonist Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

9

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

43.62 / 44.27Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

149 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat